Immunic (NASDAQ:IMUX) Releases Quarterly Earnings Results, Beats Expectations By $0.36 EPS

Immunic (NASDAQ:IMUX) posted its earnings results on Tuesday. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.36, FiscalAI reports.

Immunic Stock Performance

Shares of IMUX opened at $15.93 on Thursday. Immunic has a fifty-two week low of $5.06 and a fifty-two week high of $16.60. The firm’s 50-day simple moving average is $14.34 and its two-hundred day simple moving average is $11.96. The stock has a market cap of $216.97 million, a PE ratio of -3.64 and a beta of 1.41.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IMUX. Roth Capital reiterated a “buy” rating and issued a $19.00 price objective on shares of Immunic in a report on Thursday, May 14th. D. Boral Capital cut Immunic from a “buy” rating to a “hold” rating in a research note on Wednesday, April 15th. HC Wainwright restated a “buy” rating and set a $22.00 target price (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a report on Friday, May 29th. Finally, Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Sunday, April 19th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $47.57.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in IMUX. Jane Street Group LLC raised its stake in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after buying an additional 152,726 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Immunic by 5.3% in the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after acquiring an additional 219,957 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Immunic during the third quarter valued at $239,000. Two Sigma Investments LP bought a new position in shares of Immunic during the third quarter valued at $52,000. Finally, Virtu Financial LLC purchased a new position in shares of Immunic in the 3rd quarter worth about $99,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.